MEGA GENOMICS (06667) announces its mid-year performance for 2025, with a net profit of 27.3 million yuan.

MEGA GENOMICS (06667) released its interim performance for the six months ended June 30, 2025. During the reporting period, the company achieved a revenue of RMB 81.3 million, a year-on-year decrease of 24.2%; and a net profit of RMB 27.3 million, a year-on-year decrease of 26.3%. The decline in revenue and net profit in this period was mainly due to the company adjusting its sales strategy, leading to a phased decrease in revenue. Meanwhile, costs such as labor, rent, depreciation, etc. were relatively fixed, resulting in a decrease in net profit. As of June 30, 2025, we have collaborated with medical and healthcare institutions in over 340 cities in China. Our sales and marketing network enables us to provide genetic testing services to the majority of the Chinese population. In addition, we have partnered with several e-commerce and online healthcare platforms to expand and enhance our sales and marketing network.